Maximilian Merz, Eric Jurgens, David Fandrei, Saad Z. Usmani, Sham Mailankody
More than a decade after the initial clinical reports of chimeric antigen receptor (CAR) T-cell therapy emerging from early-phase trials and individual case studies [ 1 , 2 , 3 ]. CAR T cells directed against B-cell maturation antigen (BCMA) have now evolved into an established standard of care for patients with relapsed or refractory multiple myeloma (RRMM) [ 4 ].